This is just a tiny glimpse of the data available to CivicScience clients. Discover more data. CivicScience has data on over ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Recently, there has been a lot of buzz around GLP-1 weight loss injections. Talk of Ozempic or Wegovy has been hard to miss.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

One in eight. That's how many people living in the United States have taken some form of a glucagon-like peptide 1, otherwise known as a GLP-1, medication for weight loss and related conditions ...

LifeVantage (LFVN) announced the completion of an international in vitro cell study that investigated the effects of its international ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

GLP-1 RA medications safe and very effective for treating obesity in adults without diabetes Data also shows some very promising options that are not yet FDA approved Abstract: https://www ...

With one in eight Americans having taken a GLP-1 already — including 43% of those with diabetes and a quarter of people with heart disease — it’s time to shift our thinking on GLP-1s to ...

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications, which suppress appetite and reduce food consumption. GLP-1 drugs, popular for weight loss, are expected to ...